Browse the corpus

Hair loss disorders, such as alopecia areata (AA), androgenetic alopecia (AGA), telogen effluvium (TE), and scarring alopecias, extend beyond cosmetic concerns, carrying substantial psychosocial burden and systemic consequences underestimated in clinical care []. In addition to emotional distress, certain hair loss subtypes such as AA and primary cicatricial alopecias have been associated with broader immune and systemic conditions, including thyroid disease, systemic lupus erythematous, vitamin deficiencies, and metabolic alterations []. Flares are typically reported in association with stress, illness, or disruptions in daily routine, hinting at underlying neuroendocrine and inflammatory pathways []. Even in non-autoimmune forms such as AGA and TE, the chronic uncertainty of shedding or progression can be associated with anxiety, rumination, social withdrawal, and functional impairment []. These cumulative stressors, both psychological and physiologic, create a milieu in which sleep disturbance becomes clinically relevant []. This relationship may be bidirectional, where poor sleep may exacerbate inflammatory and hormonal dysregulation, potentially contributing to hair loss, while the distress of hair loss itself may perpetuate sleep disruption [].

Sleep disorders, such as insomnia, obstructive sleep apnea (OSA), hypersomnolence, and restless leg syndrome, are heterogeneous conditions that disrupt the quantity, quality, or timing of sleep, impairing physiologic homeostasis []. Mechanistically, sleep disruption has been associated with alterations in interleukin (IL)-6, C-reactive protein (CRP), and tumor necrosis factor-α (TNF-α) levels and activation of immune signaling []. With the hair follicle as a peripheral neuroendocrine “mini-organ” that synthesizes cortisol and responds to corticotropin releasing hormone (CRH) and substance P (SP), these changes become relevant to hair biology, potentially influencing follicle cycling and providing biologic plausibility for sleep-linked telogen shifts and immune-mediated flares in susceptible patients [, ]. Although emerging evidence links sleep disturbance to select hair loss subtypes, findings are fragmented and disease-specific []. This systematic review provides the first comprehensive synthesis examining sleep and hair loss across diverse hair loss disorders, assessing whether sleep dysregulation is associated with disease onset or progression, whether hair loss may impair sleep through psychosocial or symptomatic burden, and whether a bidirectional relationship exists.

Across the literature, the overall level of evidence across studies examining sleep and hair loss was low to moderate (1 level II, 11 level III, 14 level IV, and 3 level V), consisting primarily of cross-sectional ( n = 15) designs. There were no interventional studies. The majority focused on AA ( n = 14), followed by AGA ( n = 11), TE ( n = 3), lichen planopilaris (LPP) ( n = 1), and traction alopecia (TA) ( n = 1). Sleep outcomes were assessed using the Pittsburgh Sleep Quality Index (PSQI) ( n = 9), Epworth Sleepiness Scale (ESS) ( n = 6), Insomnia Severity Index (ISI) ( n = 1), and the Snoring, Tiredness, Observed apnea, Pressure, Body mass index, Age, Neck circumference, and Gender (STOP-BANG) questionnaire ( n = 1), with limited use of objective measures (polysomnography n = 1). An overview of study designs is provided in Table , and outcomes by hair loss subtype are summarized in Table .

Population-based studies suggest a bidirectional relationship between AA and sleep disorders, with evidence pointing to overlapping immune and endocrine pathways that regulate inflammation and autoimmunity [, –]. Sleep deprivation has been associated with a proinflammatory state by elevating IL-1, IL-6, IL-17, TNF-α, IL-21, IL-22, and IL-23, all of which are upregulated in patients with AA and are implicated in perifollicular inflammation and collapse of immune privilege [, –]. Disrupted sleep may impair regulatory T-cell activity and alter SP signaling, potentially stimulating mast cell activation, cytokine release, and aberrant major histocompatibility complex class I expression on anagen follicles and promoting catagen induction and follicular autoimmunity []. Chronic sleep loss has also been described as an endocrine stressor associated with dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, with elevations in adrenocorticotropic hormone and corticosterone that may trigger stress-induced production of antinuclear autoantibodies and promoting autoreactivity []. This mechanism may be relevant to AA, mirroring observed associations between sleep loss and other autoimmune disease, such as narcolepsy type 1, Graves’ disease, Hashimoto thyroiditis, rheumatoid arthritis, and vitiligo, which involve similar susceptibility loci such as cytotoxic T-lymphocyte–associated protein (CTLA)-4, IL2, IL21, and IL2RA that govern regulatory T-cell function [, ]. Circadian rhythm disruption may further compound these effects by altering “clock gene” expression within hair follicles, which may slow anagen progression and amplify local inflammatory signals, potentially lowering the threshold for follicular autoimmunity []. Intermittent hypoxia from OSA has also been linked to AA, though its specific mechanism remains uncharacterized [].

AA-related psychosocial stressors may further reinforce this biological vulnerability [–]. Visible hair loss is associated with social withdrawal and anticipatory anxiety that can lead to nocturnal hyperarousal and difficulty initiating sleep, particularly among women, who report greater self-consciousness and quality of life impairment [–, –]. This is supported by the consistently elevated Hospital Anxiety and Depression Scale (HADS) and Dermatology Life Quality Index (DLQI) scores in poor sleepers with AA [–, , ]. Quantitatively, reported rates of poor sleep (PSQI ≥ 5) in AA ranged from 77% to 87%, compared with 70% in controls, with the PSQI showing greater sensitivity for detecting sleep disorders in AA compared with the ESS and ISI [, , , ]. Impairments were more pronounced in patients with moderate to severe disease and those with comorbid atopic dermatitis, likely reflecting added inflammatory and psychosocial stress [, , , ]. While some studies report greater sleep disturbance within 1–3 months of disease onset, others find higher rates beyond 5 years, suggesting that acute psychosocial distress early on may evolve into chronic emotional fatigue over time [, , ]. Nevertheless, one study reported no significant difference in ESS scores between patients with AA and controls, with only 11.4% of patients with AA reporting excessive daytime sleepiness (EDS) [, ].

Overall, these findings underscore the value of routinely assessing sleep quality in patients with AA using standardized tools such as the PSQI, and poor sleep should prompt evaluation for comorbid anxiety and depression in patients with AA.

AGA is a progressive, androgen-dependent disorder driven by follicular miniaturization genetic predisposition, and hormonal mechanism that appear sensitive to circadian and metabolic regulation []. Reduced expression of the “clock gene” period circadian regulator 3 (PER3) and a later sleep onset have been linked to AGA, with proposed effects on synchronization of hair follicle cell cycles, dampening Wingless-related integration site (WNT)-dependent growth signaling, and prolongation of follicular quiescence, which are mechanisms hypothesized to contribute to follicular miniaturization []. OSA has been associated with intermittent hypoxia and oxidative stress that can raise systemic androgens and inflammatory mediators, potentially affecting follicular keratinocytes and upregulating androgen receptor activity [, ]. When combined with a family history of hair loss, OSA has been linked to nearly sevenfold increased risk of AGA, suggesting a possible gene–environment interaction []. In women, menopause-associated circadian misalignment and sleep fragmentation may impair the HPA axis, potentially suppressing gonadal hormone secretion []. This may exacerbate the mitochondrial dysfunction accompanying estrogen decline, as estrogen plays an important role in supporting oxidative phosphorylation and redox balance []. Moreover, poor sleep quality often co-occurs with unhealthy dietary and lifestyle habits that compound hormonal dysregulation [, –]. AGA patients with later bedtimes have been shown to more frequently consume sweetened beverages and high-fat, carnivorous, processed foods that may disrupt the HPA axis and be associated with increased cortisol and testosterone secretion, enhancing androgen-mediated follicular miniaturization [, –].

Across studies, severe AGA was linked to shorter total sleep times (≤ 6 h), higher PSQI scores (> 5), and elevated STOP-BANG scores (≥ 5) [, ]; ESS was less sensitive for detecting sleep disturbances in this population []. Although findings vary by age and setting, with some cohorts showing no difference in sleep quality among college-aged individuals [], the consistent associations across diverse populations support the concept that sleep disturbance, through hormonal dysregulation, oxidative stress, and circadian disruption, acts as both a marker and potential amplifier of androgen-mediated follicular miniaturization.

TE, a non-scarring, diffuse hair shedding disorder characterized by the premature transition of follicles to telogen, appears closely tied to the stress–sleep axis [, ]. Proposed mechanisms suggest that reduced or poor-quality sleep leads to dysregulation of neuropeptides such as SP, which are implicated in neuroinflammation []. SP released from peripheral nerves promotes mast-cell degranulation and inflammatory cytokine release via neurokinin-1 receptor signaling []. Experimental models demonstrate that high levels of substance P reduce sleep efficiency and increase arousal frequency, while blockade of its receptor normalizes sleep, suggesting a bidirectional relationship in which stress-induced neuropeptide imbalance may both worsen sleep and sustain follicular inflammation []. During the coronavirus disease (COVID)-19 pandemic, increased psychosocial stress and insomnia were temporally associated with TE episodes, suggesting that chronic stress, sleep disturbance, and neuroinflammatory activation may together perpetuate hair shedding []. Although restoration of high-quality sleep may normalize neuroendocrine balance and follicular cycling [], longitudinal studies using objective sleep measures are needed to confirm causality.

LPP is a lymphocyte-mediated cicatricial alopecia in which chronic perifollicular inflammation leads to irreversible follicular destruction and scarring []. The inflammatory process in LPP extends beyond the scalp, producing pain, burning, and pruritis that are associated with impaired sleep quality []. Psychological distress related to hair shedding in LPP has also been linked to sleep disruption []. Patients with LPP demonstrate significantly higher PSQI scores (mean 7.4 in LPP versus 5.1 in controls), reflecting worse overall sleep and prolonged sleep latency []. Sleep disturbance correlates with disease duration and lower quality of life, likely reflecting persistent inflammation and psychosocial burden []. Demographic factors such as sex, occupation, and site of scalp involvement have shown no association with sleep outcomes []. These findings underscore that chronic inflammation in LPP is closely linked to sleep impairment through cumulative systemic and psychological stress, emphasizing the importance of effective disease control in restoring sleep quality.

TA is a mechanical form of hair loss resulting from chronic or repetitive tension on hair []. Sleep-related grooming habits, such as wearing tight curlers or pony-tail hairstyle overnight, have been associated with gradual follicular damage and are recognized contributors to TA []. While nocturnal hair tension is increasingly recognized as a risk factor for TA [], literature examining the relationship between sleep quality and TA remains limited.

Sleep disruption has been associated with hair loss through neuroendocrine, immune, and metabolic pathways that vary by disease subtype [, ], as depicted in Fig. . In AA, sleep loss has been linked to systemic inflammation, HPA axis dysregulation, and altered clock gene expression, with downstream changes that may amplify autoreactivity by elevating IL-1, IL-6, IL-17, TNF-α, and IL-23, impaired regulatory T-cell activity, and disruption of follicular immune privilege [, –]. In AGA, sleep disruption, through mechanisms such as menopausal circadian misalignment, late-night dietary patterns, and OSA, has been associated with oxidative stress and hormonal imbalance that may disturb the HPA axis and mitochondrial function, potentially increasing the androgen activity implicated in follicular miniaturization [, –]. In TE, chronic stress and fragmented sleep have been associated with elevations in substance P and inflammatory cytokines, which may contribute to premature anagen-to-telogen transition []. In LPP, sustained perifollicular inflammation and pruritic symptoms are frequently associated with impaired restorative sleep, in addition to disease-related psychological burden [].

The interplay between poor sleep and disease activity is increasingly recognized in dermatology. In atopic dermatitis, over 40% of patients experience clinically significant sleep disturbance, which has been shown to improve with effective treatment such as dupilumab [, ], indicating how sleep quality may both reflect and reinforce inflammatory burden. Similarly, in acne, insufficient sleep has been associated with greater inflammatory lesion counts and hormonal imbalance, whereas restorative sleep has been linked to balanced sebum production and barrier function [, ]. These patterns suggest that sleep may function as more than a bystander and could act as a disease modifier. Incorporating validated tools such as the PSQI into hair loss assessment and addressing modifiable sleep disorders such as insomnia or OSA through hygiene education or medical referral may enhance disease stability, treatment responsiveness, and overall quality of life.

Building on this framework, targeted sleep interventions offer practical, evidence-based strategies to mitigate the neuroendocrine and inflammatory stressors associated with hair loss. Sleep hygiene strategies, such as avoiding late-day caffeine and alcohol, maintaining consistent sleep timing, exercising regularly, and optimizing noise, light, and temperature support circadian stability [–]. These modifications can be incorporated into cognitive behavioral therapy for insomnia (CBT-I), the first-line treatment for insomnia that combines stimulus control, relaxation techniques, cognitive restructuring, and structured education. Low risk nutraceuticals such as melatonin may be recommended; other options include magnesium, omega-3 fatty acids, tart cherry juice, kiwifruit, apigenin, valerian root, l -theanine, glycine, ashwagandha, myo-inositol, Rhodiola rosea , and phosphatidylserine []. Pharmacologic therapies, such as benzodiazepines, Z-drugs, ramelteon, low-dose doxepin, certain antidepressants, and antihistamines, can improve short-term sleep outcomes but carry varying risks of dependence or adverse effects []. For dermatologists, integrating these interventions as summarized in Table may provide a low-burden, high-impact way to reduce physiologic stress, improve sleep quality, and potentially support greater disease stability.

The limitations of this study are inherent in its design as a systematic review, given the heterogeneity and limited level of evidence of available studies, most of which were cross-sectional, relied on self-reported sleep questionnaires, and rarely incorporated objective measures such as actigraphy or polysomnography. These limitations precluded causal inference and left confounders such as stress, hormonal variation, psychiatric comorbidity, and medication use. The literature remains fragmented, focusing primarily on AA and AGA, with minimal exploration of scarring alopecias. Future research should employ longitudinal designs integrating sleep biomarkers and standardized hair metrics (Sinclair, trichoscopy) to elucidate temporal and mechanistic links. Clinically, dermatologists can begin incorporating brief, validated sleep assessments into routine hair loss evaluations and consider collaboration with sleep medicine specialists, as optimizing sleep may serve as a low-risk, adjunctive strategy to improve treatment outcomes and overall patient well-being.

Sleep disturbance is an underrecognized yet biologically plausible factor associated with hair loss disorders, intersecting neuroendocrine, inflammatory, and metabolic pathways implicated in follicular health. While current evidence is limited and largely observational, emerging data support incorporating sleep assessment into dermatologic practice as part of holistic hair loss care. Future longitudinal and mechanistic studies are needed to clarify causality and identify therapeutic targets, but for now, optimizing sleep may represent a simple, low-risk adjunct that may enhance hair outcomes. Recognizing sleep health as an integral component of dermatologic care reframes management from treating isolated lesions to restoring systemic physiologic balance.